hit counter

Olanzapine for Anorexia: A Promising Treatment Both Systemically & Intranasally (2023 Study)

Anorexia nervosa (AN), a severe mental disorder characterized by an intense fear of gaining weight and a distorted body image, remains a formidable challenge in psychiatric treatment. Recent research has shone a light on the potential of olanzapine, an atypical antipsychotic, in offering new hope through both systemic and innovative intranasal administration methods in animal …

Read more

Quetiapine-Induced Psychosis: A Rare Adverse Effect (2024 Case Report)

Quetiapine, a second-generation antipsychotic medication, is renowned for its efficacy in managing a spectrum of psychiatric conditions, including schizophrenia, bipolar disorder, and major depressive disorder (MDD). Despite its broad therapeutic utility and a generally favorable side effect profile, quetiapine’s role in rare instances of inducing psychotic symptoms warrants a closer examination. Highlights: Quetiapine’s Mechanism of …

Read more

How People Feel About Antipsychotics & Mood Stabilizers: Twitter/X Sentiment Analysis (2024 Study)

Social media has emerged as a pivotal source of real-world evidence, especially in understanding patient experiences and perceptions regarding the treatment of severe mental disorders such as Schizophrenia and related psychotic disorders (SRD) and Bipolar Disorder (BD). Leveraging advanced artificial intelligence (AI) techniques, a comprehensive analysis of 893,289 tweets between 2008 and 2022 revealed significant …

Read more

Comparison of Brexipiprazole vs. Aripiprazole for Treatment-Resistant Depression (2024 Study)

Antidepressant-resistant major depressive disorder (AR-MDD) poses significant challenges in psychiatric treatment. Antipsychotics like aripiprazole (ARI) and brexpiprazole (BRE) have emerged as effective adjunct therapies that may be more tolerable than older antipsychotics. Highlights: Both Brexipiprazole and Aripiprazole demonstrated better efficacy than placebo in treating AR-MDD in Japanese patients. Brexipiprazole showed a higher discontinuation rate due …

Read more

Quetiapine Dosing for Depression Optimized with XGBoost Algorithm (2024 Study)

Depression is a globally pervasive mental illness that often requires complex treatment strategies. One such strategy involves the use of Quetiapine, an antipsychotic medication, as an augmentation to antidepressants. However, determining the optimal dose of Quetiapine is challenging due to individual variability. A recent study utilizes machine learning techniques to develop a predictive model for …

Read more

Metformin Prevents Antipsychotic-Induced Weight Gain: A Saudi Study Finds

Research suggests that metformin may reduce weight gain associated with antipsychotic medications. Key facts: Antipsychotics are linked to weight gain, especially clozapine and olanzapine. Metformin may counteract antipsychotic-induced weight gain through effects on insulin resistance and appetite. Study found metformin reduced mean weight gain on antipsychotics from 2.5 kg to -0.04 kg. Younger patients ages …

Read more

Rexulti (Brexpiprazole) Withdrawal Symptoms: What You Should Know

Rexulti (Brexpiprazole) is an atypical antipsychotic that is most commonly utilized as a pharmacologic intervention for the management of schizophrenia, and in some cases, as an add-on (adjunct) treatment for refractory major depressive disorder.  Throughout the central nervous system, the medication exerts neurophysiologic effects across dopaminergic, serotonergic, noradrenergic, and histaminergic targets. Receptor sites most targeted …

Read more